← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2003Last known activity
Sep 25, 2024
Timeline
1990s
- Jun 1, 1996
Doris Duke Charitable Foundation— Founded
Drugs by trial phase (39 distinct, 29 trials)
Phase 4 (7 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (9 own, 0 via acquisition)
Other trials (6 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Anemia, Sickle Cell
- Carcinoma, Renal Cell
- Carotid Stenosis
- Colorectal Neoplasms
- Hypercholesterolemia
- Hyperlipoproteinemia Type II
- Inflammation
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma, Non-Hodgkin
- Malaria
- Myelodysplastic Syndromes
- Pneumonia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recent trials (29)
- NCT06212271CollaboratorEarly Phase 1Sep 25, 2024
- NCT06358638CollaboratorPhase 2Apr 3, 2024
- NCT06016634CollaboratorPhase 2Jan 31, 2024
- NCT06116526CollaboratorPhase 4Jan 1, 2024
- NCT05705427CollaboratorPhase 4Aug 17, 2023
- NCT05980156CollaboratorPhase 4Feb 13, 2023
- NCT05539729CollaboratorPhase 1Nov 8, 2022
- NCT05391230CollaboratorN/AJun 3, 2022
- NCT05244954CollaboratorPhase 4Feb 1, 2022
- NCT04817345CollaboratorPhase 2Jan 31, 2022
- NCT05057806CollaboratorEarly Phase 1Nov 30, 2021
- NCT04828031CollaboratorPhase 1Jul 1, 2021
- NCT04587128CollaboratorPhase 2Oct 19, 2020
- NCT03789591CollaboratorPhase 3Jan 17, 2019
- NCT03128515CollaboratorPhase 3May 1, 2017
Details
- Founded
- New York, NY, US Jun 1, 1996
- Last known activity
- Sep 25, 2024